Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Janssen’s Ebola vaccine accepted for WHO emergency usage review

Janssen’s Ebola vaccine accepted for WHO emergency usage review

14th September 2016

Janssen has announced that its preventive Ebola prime-boost vaccine regimen has been accepted for review by the World Health Organization (WHO).

The global health body has accepted Janssen's submission for emergency use assessment and listing (EUAL) of the heterologous prime-boost vaccine regimen, developed in conjunction with Bavarian Nordic.

EUAL is a special procedure implemented when there is an outbreak of a disease with high rates of morbidity or mortality and a lack of treatment or prevention options. In the last four decades, there have been 25 Ebola outbreaks, with the most recent in West Africa killing seven times more people than all previous outbreaks combined.

Phase I results from a UK study of Janssen's vaccine indicated that the regimen was well-tolerated and immunogenic, with 100 percent of participants achieving an initial antibody response that was sustained eight months following vaccination among all volunteers.

Dr Johan Van Hoof, global therapeutic area head for infectious diseases and vaccines at Janssen, said: "If listed for emergency use, the investigational Janssen vaccine regimen could be a vital prevention tool for rapid outbreak response, particularly for health workers and vulnerable communities on the frontlines."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801825160-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.